Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Champions Oncology (CSBR) over the last 7 years, with Q4 2025 value amounting to $13000.0.

  • Champions Oncology's Asset Writedowns and Impairment rose 10622.01% to $13000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$8000.0, marking a year-over-year increase of 7894.74%. This contributed to the annual value of -$272000.0 for FY2025, which is 15714.29% down from last year.
  • According to the latest figures from Q4 2025, Champions Oncology's Asset Writedowns and Impairment is $13000.0, which was up 10622.01% from -$29000.0 recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Asset Writedowns and Impairment ranged from a high of $724000.0 in Q2 2023 and a low of -$209000.0 during Q4 2024
  • Moreover, its 4-year median value for Asset Writedowns and Impairment was $48000.0 (2025), whereas its average is $76538.5.
  • Within the past 5 years, the most significant YoY rise in Champions Oncology's Asset Writedowns and Impairment was 27021.28% (2024), while the steepest drop was 39027.78% (2024).
  • Over the past 4 years, Champions Oncology's Asset Writedowns and Impairment (Quarter) stood at $130000.0 in 2022, then plummeted by 44.62% to $72000.0 in 2023, then tumbled by 390.28% to -$209000.0 in 2024, then soared by 106.22% to $13000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $13000.0 for Q4 2025, versus -$29000.0 for Q3 2025 and $48000.0 for Q2 2025.